OMAVELOXOLONE
Skyclarys (omaveloxolone) is a small molecule pharmaceutical. Omaveloxolone was first approved as Skyclarys on 2023-02-28. It is used to treat friedreich ataxia in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Skyclarys
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Omaveloxolone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SKYCLARYS | REATA PHARMS | N-216718 RX | 2023-02-28 | 1 products, RLD, RS |
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| friedreich ataxia | Orphanet_95 | D005621 | G11.11 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
OMAVELOXOLONE, SKYCLARYS, REATA PHARMS | |||
| 2030-02-28 | ODE-427 | ||
| 2028-02-28 | NCE | ||
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 2 | 1 | — | — | 1 | 3 |
| Inflammation | D007249 | MP_0001845 | — | — | 2 | — | — | — | 2 |
| Friedreich ataxia | D005621 | Orphanet_95 | G11.11 | — | 1 | — | — | — | 1 |
| Mitochondrial myopathies | D017240 | Orphanet_206966 | G71.3 | — | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Corneal endothelial cell loss | D055954 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OMAVELOXOLONE |
| INN | omaveloxolone |
| Description | Omaveloxolone, sold under the brand name Skyclarys, is a medication used for the treatment of Friedreich's ataxia. It is taken by mouth.
|
| Classification | Small molecule |
| Drug class | steroids (not prednisolone derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)CC[C@]2(NC(=O)C(C)(F)F)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]3(C)CC[C@H]3C(C)(C)C(=O)C(C#N)=C[C@]43C)[C@@H]2C1 |
Identifiers
| PDB | — |
| CAS-ID | 1474034-05-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4303525 |
| ChEBI ID | — |
| PubChem CID | 71811910 |
| DrugBank | DB12513 |
| UNII ID | G69Z98951Q (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Skyclarys – Biogen
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 508 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use